hansa medical research ab
(HMED:Stockholm)
hansa medical research ab (HMED) Snapshot
|
Open
kr4.37
|
Previous Close
kr4.37
|
|
|
Day High
kr4.37
|
Day Low
kr4.21
|
|
|
52 Week High
12/18/12 - kr5.90
|
52 Week Low
10/23/12 - kr2.42
|
|
|
Market Cap
93.6M
|
Average Volume 10 Days
10.6K
|
|
|
EPS TTM
kr-1.19
|
Shares Outstanding
22.2M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
hansa medical research ab (HMED) Related Businessweek News
No Related Businessweek News Foundhansa medical research ab (HMED) Details
Hansa Medical AB operates as a biotechnology research and development company that focuses on the treatment and diagnosis of inflammation. It is developing two preclinical biopharmaceutical programs, including anti-alpha-11 for the treatment of rheumatoid arthritis; and IdeS for treatment in connection with organ transplantation. The company is also developing a clinical-stage diagnostic method, HMD-301, for the prognosis and diagnosis of severe sepsis. Hansa Medical AB has collaboration agreements with Axis-Shield plc to develop Heparin Binding Protein as a biomarker for severe sepsis; and Inverness Medical Innovations Inc. and Biosite Inc. to develop anti-alpha-11 antibodies. The company was founded in 2001 and is based in Lund, Sweden.
hansa medical research ab (HMED) Key Developments
Hansa Medical AB reported group earnings results for the year 2012. For the year, the company's net sales were SEK 2.6 million compared with SEK 1.3 million a year ago. The group’s net loss was SEK 16.5 million compared with SEK 24.6 million a year ago. Operating loss for the group amounted to SEK 16.8 million compared with SEK 24.5 million a year ago. Loss per share was SEK 0.78 compared with SEK 2.26 a year ago.
Hansa Medical AB, Annual General Meeting, May 06, 2013.
Hansa Medical AB reported group earnings results for the second half and full year ended December 31, 2011. For the second half year, on group basis, the company reported net sales of SEK 882,433 against SEK 4,157,241 for the same period in the last year. Operating loss was SEK 14,075,335 against SEK 12,495,999 for the same period in the last year. Loss after financial items was SEK 14,030,169 against SEK 12,495,223 for the same period in the last year. Loss was SEK 14,030,234 against SEK 11,195,126 for the same period in the last year. Loss per share was SEK 1.04 against SEK 1.45 for the same period in the last year. For the year, on group basis, the company reported net sales of SEK 1,282,219 against SEK 4,448,186 for the same period in the last year. Operating loss was SEK 24,464,324 against SEK 19,992,855 for the same period in the last year. Loss after financial items was SEK 24,571,956 against SEK 20,143,336 for the same period in the last year. Loss was SEK 24,572,021 against SEK 18,843,239 for the same period in the last year. Loss per share was SEK 2.26 against SEK 2.44 for the same period in the last year. Cash flow from operating activities was SEK 27,139,111 against SEK 18,093,957 for the same period in the last year.
| Recently Viewed | |||
| HMED:SS | kr4.21 SEK | -0.16 | |
| Company | Last | Change | |
| No competitor information is available for HMED. | |||
| View Industry Companies | |||
Industry Analysis
HMED
Industry Average
| Valuation | HMED | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 17.0x |
|
| Price/Book | 1.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 13.6x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact HANSA MEDICAL RESEARCH AB, please visit www.hansamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








